Table 2.

Continuation status with asenapine administration

	Continuation [n (%)]	Discontinuation [n (%)]	Total
Predictors from multivariate logistic regression analysis
CP equivalent (n = 3190)
< 600 mg/day	751 (37.6%)	1249 (62.5%)	2000
≥ 600 mg/day	551 (46.3%)	639 (53.7%)	1190
Duration of illness (n = 2506)
< 25 years	673 (37.1%)	1142 (62.9%)	1815
≥ 25 years	331 (47.9%)	360 (52.1%)	691
Combination of predictors (n = 2469)
< 600 mg/day and < 25 years	409 (34.1%)	791 (65.9%)	1200
< 600 mg/day and ≥ 25 years	145 (43.7%)	187 (56.3%)	332
≥ 600 mg/day and < 25 years	256 (43.2%)	336 (56.8%)	592
≥ 600 mg/day and ≥ 25 years	181 (52.5%)	164 (47.5%)	345
Safety status
Side effect(s) (n = 3236)
With	253 (23.0%)	845 (77.0%)	1098
Without	1062 (49.7%)	1076 (50.3%)	2138
Severe side effect (n = 3236)
With	21 (20.6%)	81 (79.4%)	102
Without	1294 (41.3%)	1840 (58.7%)	3134

CP: Chlorpromazine